On-line Diabetes Resources
This Web page brings together in one place descriptions of and links to those Web pages of companies marketing medications for blood glucose control and certain complications of diabetes. In some cases, where company information is particularly sparse, it is augmented by information on other Web sites. A separate Web page describes and links insulin at http://www.mendosa.com/insulin.htm. These pages are also linked to the 15 other On-line Diabetes Resources pages dealing with other Web pages, other parts of the Internet, and other on-line services. Those links that I think are especially valuable are marked in red. Part 11: Diabetes Medications Web Sites
By David Mendosa
Tracking Diabetes on the Web Since 1995
Most Recent Update: April 18, 2008
On-line Medication Resources |
|
|
Oral hypoglycemic agents or "diabetes pills" are used to treat type 2 diabetes. They are not insulin. This Web page lists the classes of these medications currently available, the brand (and generic names), the companies marketing them in the United States, and the Web sites of those companies. The classes are listed in order of introduction, and within the classes the medications are listed in alphabetical order by generic name: Tolbutamide was discovered in Germany in 1954 and in November 1955 began clinical trials in the United States, according to an article by William L. Laurence in the February 24, 1957, issue of The New York Times ("Science in Review: Drug for the Treatment of Diabetes Tested And Found of Great Importance," p. 179). "It is being produced in this country by the Upjohn Company of Kalamazoo, Mich., under the trade name Orinase." This new class of drugs enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. This new class of drugs enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. Oral Hypoglycemic Agents—"Diabetes Pills"
Sulfonylureas
Sulfonylureas help the body release more insulin.
First Generation Sulfonylureas (marketed before 1984)
Rarely prescribed
Eli Lilly and Company
A generic name product is available.
Pharmacia & Upjohn Inc.
Pharmacia & Upjohn advises that the company stopped making Orinase in 2000.
A generic name product is available.
Pharmacia & Upjohn Inc.
http://pharmacia.com/prescription/PDF_Current/Tolinase.pdf has full prescribing information as of January 2000.
A generic name product is also available.
Second Generation Sulfonylureas (i.e., marketed since 1984)
Sanofi-Aventis S.A.
The Amaryl site is
http://www.amaryl.com/ A generic name product also became available in October 2005.
Not commercially available in the U.S., but for sale in Canada, Australia, New Zealand, South Africa, etc. Other brand names include Ziclin and Glucomed. No product-specific Web site.
Pfizer Inc.
The Pfizer site has prescribing information at
http://www.pfizer.com/pfizer/download/uspi_glucotrol_xl.pdf
A generic name product is also available.
Aventis S.A.
http://www.aventis-us.com/PIs/diabeta_TXT.html has prescribing information as of April 2004.
A generic name product is also available.
Pharmacia & Upjohn Inc.
http://pharmacia.com/prescription/PDF_Current/Glynase.pdf has prescribing information as of January 2000.
A generic name product is also available.
Pharmacia & Upjohn Inc.
http://pharmacia.com/prescription/PDF_Current/Micronas.pdf has prescribing information as of January 2000.
A generic name product is also available.
Biguanides
Biguanides make the insulin the body is producing work better.
The U.S. Food and Drug Administration approved the marketing of metformin in May 1995. Bristol-Myers Squibb Company
Glucophage
Bristol-Myers Squibb Company
Glucophage XR is a once-daily dosage form of Glucophage.
Glucophage XR
Alpha-Glucosidase
Alpha-Glucosidase inhibitors delay the digestion of sugars and starches.
The U.S. Food and Drug Administration approved the marketing of Precose in September 1995. Known as Prandase in Canada
Bayer Corporation's Pharmaceutical Division, North America
http://www.bayerpharma-na.com/products/co03precose.asp
Prescribing Information: http://www.univgraph.com/Bayer/inserts/Precose.pdf
Pharmacia & Upjohn Inc. has been granted marketing rights to Bayer's miglitol for marketing in the United States, Canada, Australia, and New Zealand under the tradename Glyset. The U.S. Food and Drug Administration approved the marketing of Glyset in December 1996. Sanofi holds the European rights to miglitol and has launched it in Germany as Diastabol. Bayer recently granted Sanwa Kagaku Japanese development rights to the product.
http://pharmacia.com/prescription/PDF_Current/Glyset.pdf has full prescribing information as of September 1999.Thiazolidinedione
Thiazolidinedione makes the insulin the body is producing work better.
Avandia is a treatment for type 2 diabetes developed by GlaxoSmithKline that the U.S. Food and Drug Administration approved in May 1999. By reducing insulin resistance Avandia significantly improves blood sugar control. The company's Web site is
http://www.avandia.com/
Developed by Japan's Takeda Chemicals Industries Ltd. and marketed in the United States by Eli Lilly, Actos was approved by the U.S. Food and Drug Administration in July 1999. The URL is
http://www.actos.com/
Meglitinide
Meglitinide stimulates insulin secretion from the beta cells of the pancreas.
The U.S. Food and Drug Administration approved the sale of Prandin in December 1997.
Known as NovoNorm in Europe and outside North America and GlucoNorm in Canada
Novo Nordisk A/S
http://www.novonordisk-us.com/view.asp?ID=61
and
http://www.novonordisk-us.com/view.asp?ID=1284Amino acid D-phenylalanine Derivative
This drug restores early insulin secretion.
In December 2000 the Food and Drug Administration approved U.S. marketing of this new drug from Novartis Pharma AG.
http://www.starlix.com
Prescribing Information: http://www.pharma.us.novartis.com/product/pi/pdf/Starlix.pdfAmylinomimetics
Symlin injection is a synthetic analog of human amylin. It is the first member of a new class of amylinomimetic compounds. The U.S. Food and Drug Aministration approved it in March 2005.
http://www.symlin.com/Incretin Mimetics
In April 2005 the Food and Drug Administration approved U.S. marketing of this new drug from Amylin Pharmaceuticals Inc. and Eli Lilly and Company.
http://www.byetta.com
Prescribing Information: http://pi.lilly.com/us/byetta-pi.pdf
DPP-4 Inhibitors
The Food and Drug Administration approved Januvia for type 2 diabetes on October 17, 2006, as both monotherapy and as add-on therapy to either of two other types of oral diabetes medications, metformin or thiazolidinediones. Januvia doesn't help people with type 1 diabetes or diabetic ketoacidosis. Merck & Co. markets Januvia in the United States.
Prescribing Information: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf
Combinations
These drugs combine two oral medications.
Merck & Co. Inc.
http://www.janumet.com/sitagliptin_metformin_HCl/janumet/index.jsp
Takeda Pharmaceuticals North America Inc.
http://www.takeda.co.jp/english/press/04102901.htm
GlaxoSmithKline
http://us.gsk.com/
GlaxoSmithKline
http://www.avandia.com/about_avandaryl/avandaryl.html?a=238
Bristol-Myers Squibb Company
http://www.glucovance.com/
Bristol-Myers Squibb Company
http://www.bms.com/landing/data/index.html
Other Resources |
|
NovoMedLink Diabetes Patient Care has diabetes patient care information and resources for health care professionals. The URL is An excellent (albeit not completely up to date) website about forthcoming drugs is maintained by the Pharmaceutical Research and Manufacturers of America (the trade or lobbying group) at World-wide sales of oral diabetes medications reached $7.8 billion in 2003, according to analysts from SG Cowen Securities Corporation, a U.S. securities and investment banking firm focused on the emerging growth sectors of health care and other markets. This includes glitazones, $3.6 billion; sulfonylureas, $1.0 billion, and other, $3.7 billion (meanwhile insulin sales totalled $4.7 billion). They reported this at a March 2004 investment conference in Boston last week, according to Kelly Close in Diabetes Close Up, V3, #6 March 17, 2004. Her website is http://www.closeconcerns.com. Please also refer to my article in the September 2000 issue of Diabetes Wellness Letter, "Smart Drugs: Are We Ready For Them?" This article is online at http://www.mendosa.com/starlix.htm. The May 1998 issue of Diabetes Wellness Letter, included another article about new hypoglycemic agents, "Beyond Sulfonylureas: The New Drugs for Blood Glucose Control." This article is online at http://www.mendosa.com/newdrugs.htm Good sources for additional information about several of these drugs are PharmInfoNet, Medications, http://www.pharmacytimes.com/diabetesce.html, and Oral Diabetes Medication Information. The Geriatric Drug Review: Diabetes by Alan Lukazewski, Registered Pharmacist and Certified Diabetes Educator, is a valuable resource for anyone over 50 who has diabetes. This is probably the most important Web page about diabetes on AgeNet, which provides resources for older adults and caregivers. The site also has an "Ask a Pharmacist" area where visitors can e-mail a pharmacist and Certified Diabetes Educator about drugs specific to the aging population. The URL is |
Diabetes can lead to several complications. The best starting point for the various complications is the Diabetes Monitor's Web page Complications and their Prevention Medications for three of the most common complications include: Also see Captopril Approved for Treating Diabetic Kidney Disease on the FDA site. Selected Medications for Diabetic Complications
Otsuka America Pharmaceutical Inc.
Pletal (cilostazol) is a new medicine for intermittent claudication, which is a symptom of peripheral arterial disease. PAD is one of the most significant health problems affecting older people with diabetes. Most people know PAD as "hardening of the arteries." You also may have heard it called atherosclerosis.
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Products: searching here for Capoten (captopril) returns full prescribing information in PDF format.
Ortho-McNeil Pharmaceutical Inc.
REGRANEX (becaplermin) Gel 0.01%
Organogenesis Inc.
Organogenesis Inc. in Canton, Massachusetts, had developed Apligraf (Graftskin), a manufactured skin construct. In June 2000 the Food and Drug Administration has approved Apligraf for use with conventional diabetic foot ulcer care in the treatment of diabetic foot ulcers of greater than 3 weeks duration. Novartis Pharma AG has global marketing rights for Apligraf.
Advanced Tissue Sciences Inc.
Advanced Tissue Sciences Inc. in La Jolla, California, sells Dermagraft in Canada, the United Kingdom, several other European countries, Australia, and New Zealand. The FDA in October 2001 approved the Premarket Approval Application (PMA) for Dermagraft in the treatment of chronic foot ulcers in patients with diabetes in the United States.Intermittent Claudication
Diabetic Nephropathy
Foot Ulcers
Clinical Trials |
| The pre-clinical trials for most drugs average about 18 months, according to the FDA or 5 years, according to Zeke Ashton on The Motley Fool. Clinical trials normally take another 2 to 10 years, according to the FDA and 5 to 9 years, according to Zeke Ashton. The FDA review process takes 2 months to 7 years, averaging 24 months, the FDA says.
The current costs of bringing a new medicine to market are estimated to be as high as $0.8 to 1.7 billion. The The Food and Drug Administration says that of 100 drugs for which developers submit investigational new drug applications are submitted to it, about 70 will successfully complete phase 1 trials and go on to phase 2. About 33 of the original 100 will complete phase 2 and go to phase 3. And 25 to 30 of the original 100 will clear phase 3. Therefore, on average, about 20 of the original 100 will ultimately be approved for marketing. There has been an explosion of Web sites matching patients with manufacturers who are testing proposed drugs in clinical trials. I wrote about some of them for my ADA column "About the Internet" in May 2000 at: http://www.mendosa.com/clinicaltrials.htm, but there are now several more:
|
© Copyright 2009 David Mendosa. All Rights Reserved. You may quote part of this page in on-line documents and printed publications, but please notify me so I can add a reference and make sure that you add pointers to the places where people can get the latest version. Permission to link this site to yours is not needed. Of course, I would be delighted to hear from you, especially if you have a new site that you think should be linked here. I have no control over the content or continued existence of any external on-line resources linked here, and I therefore cannot guarantee that they will function as promised. The appearance of a site on this list does not imply any endorsement by me. Since this information is constantly changing, readers are urged to email corrections and updates to me at mendosa@mendosa.com. If you have a question about your health, please go to either Diabetes Questions & Answers at the Diabetes Monitor, or use the Question Form for the Diabetes Team at Children with Diabetes.
Go to Insulin Resources Page
Go back to Medline Web Resources Page
993 E. Moorhead Circle Suite 2F
Boulder, Colorado 80305
E-mail: mendosa@mendosa.com
